Researchers identified a key receptor that primes the formation of autoreactive B cells. Disrupting this pathway may be a ...
Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with ...
The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...
Mucosa-associated lymphoid tissue (MALT) lymphomas are slow-growing B-cell lymphomas mainly diagnosed in the stomach and termed gastric MALT lymphoma (G-MALT). Despite histological evaluation, ...
As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
“[...] our findings suggest that the age-related decrease in response following influenza vaccination could reflect functional alterations in activated B cells ...
Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...
A new method, developed at Karolinska Institutet, KTH Royal Institute of Technology and SciLifeLab in Sweden, can identify unique immune cell receptors and their location in tissue, a study published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback